MedImmune CEO talks about AZ buyout

MedImmune's chief executive talked publicly for the first time about AstraZeneca's April takeover of his company--and his assessment of his new corporate parent is, not surprisingly, positive. David M. Mott did get to keep his job, and MedImmune is adding to its staff of 3,000, rather than slicing away at jobs as the rest of AstraZeneca is. Plus, Mott expects R&D spending to ramp up significantly, to $1 billion by 2010 from $400 million last year. Big Pharma is fun, he essentially said. It probably helps that he made a cool $145 million off the deal himself.

- check out the report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.